Single‐atom Pt‐N‐C nanozyme targets Rara/Wnt/β‐catenin axis for diabetic cardiomyopathy treatment

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Abstract Background and Purpose Diabetic cardiomyopathy (DCM) lacks effective therapies because of complex mechanisms. This study aims to develop a single‐atom nanozyme for integrated antioxidant and signalling regulation in DCM. Experimental Approach A graphene quantum dot‐templated single‐atom Pt‐N‐C nanozyme (PtsaN‐C) was synthesised for all‐trans retinoic acid (ATRA) delivery (PtsaN‐C@ATRA). In vitro antioxidant activity and in vivo efficacy were evaluated in DCM mice, combined with scRNA‐seq for mechanistic analysis. Key Results PtsaN‐C@ATRA improved cardiac function, reduced fibrosis/apoptosis and activated the Rara/Wnt/β‐catenin axis to promote cardiomyocyte differentiation. Conclusions and Implications PtsaN‐C@ATRA represents a novel strategy merging nanozyme catalysis with transcriptional regulation, offering potential for clinical translation in DCM.